Delfi Diagnostics
Blood-based diagnostic test for early lung cancer detection using circulating tumor DNA analysis
- Sector
- Medtech
- Headquarters
- Palo Alto, CA
- Founded
- 2018
- Latest Form D
- $34.3M, Dec 2025
- Total capital
- $366M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $366M
- 5 Form D · last Dec 2025
- 10 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 26 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$34.3M
- Private capital raisedForm D · SEC · 4th filing$225M
- Private capital raisedForm D · SEC · 3rd filing$101M
- Private capital raisedForm D · SEC · 2nd filing$5.5M
- Private capital raisedForm D · SEC · 1st filing$15K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Amoolya B. SinghExecutive OfficerNamed in SEC Form D filings
- Douglas SchenkelExecutive OfficerNamed in SEC Form D filings
- Elizabeth HomansDirectorNamed in SEC Form D filings
- Greg YapDirectorNamed in SEC Form D filings
- Jacob B. Van NaardenDirectorNamed in SEC Form D filings
- Jennifer BuechelExecutive OfficerNamed in SEC Form D filings
Show all 15 people
- Justin KaoDirectorNamed in SEC Form D filings
- Lee-Ann B. Smith-FreemanExecutive OfficerNamed in SEC Form D filings
- Michael B. DybbsDirectorNamed in SEC Form D filings
- Nicholas J. DracopoliExecutive OfficerNamed in SEC Form D filings
- Peter B. BachExecutive OfficerNamed in SEC Form D filings
- Rishi B. GuptaDirectorNamed in SEC Form D filings
- Susan TousiExecutive Officer, DirectorNamed in SEC Form D filings
- Victor VelculescuExecutive Officer, DirectorNamed in SEC Form D filings
- William StevensExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 26- PendingIncorporating Clinical Risk Into Biomarker-based Assessment For Cancer Pre-screeningUSPTOApplication 19115216
- PendingWorkflows For Discovery And Deployment Of Diagnostic Assays Combining Proteomic And Genomic InformationUSPTOApplication 19187960
- PendingUse Of Cell-free Dna Fragmentomes In The Diagnostic Evaluation Of Patients With Signs And Symptoms Suggestive Of CancerUSPTOApplication 18864428
Show all 26 patent records
- Incorporating Clinical Risk Into Biomarker-based Assessment For Cancer Pre-screeningApr 16, 2026 · Application 19115216Pending
- Workflows For Discovery And Deployment Of Diagnostic Assays Combining Proteomic And Genomic InformationOct 23, 2025 · Application 19187960Pending
- Use Of Cell-free Dna Fragmentomes In The Diagnostic Evaluation Of Patients With Signs And Symptoms Suggestive Of CancerOct 23, 2025 · Application 18864428Pending
- Method Of Monitoring Cancer Using Fragmentation ProfilesJun 5, 2025 · Application 18844348Pending
- Method Of Detecting Cancer Using Genome-wide Cfdna Fragmentation ProfilesMar 6, 2025 · Application 18286081Pending
- Methods And Systems For Cell-free Dna Fragment Size Densities To Assess CancerSep 28, 2023 · Application 18019448Pending
- Delfi-derived Cell-free Dna Fragmentation Patterns Differentiate Histologic Subtypes Of Lung Cancers In A Non-invasive MannerApplication 63528237Pending
- Dissecting Small Cell Lung Cancer Subtypes With Cell-free Dna FragmentomesApplication 63470101Pending
- Use Of Cell-free Dna Fragmentomes In The Diagnostic Evaluation Of Patients With Signs And Symptoms Suggestive Of CancerApplication PCTUS2023022104Pending
- Method Of Monitoring Cancer Using Fragmentation ProfilesApplication PCTUS2023015559Pending
- Dissecting Small Cell Lung Cancer Subtypes With Cell-free Dna FragmentomesApplication 63445284Pending
- Incorporating Clinical Risk Into Biomarker-based Assessment For Cancer Pre-screeningApplication 63414370Pending
- Use Of Cell-free Dna Fragmentomes In The Diagnostic Evaluation Of Patients With Signs And Symptoms Suggestive Of CancerApplication 63341323Pending
- Method Of Detecting Cancer Using Genome-wide Cfdna Fragmentation ProfilesApplication PCTUS2022023907Pending
- Method Of Monitoring Cancer Using Fragmentation ProfilesApplication 63320906Pending
- Methods And Systems For Cell-free Dna Fragment Size Densities To Assess CancerApplication PCTUS2021046272Pending
- Method Of Detecting Cancer Using Genome-wide Cfdna Fragmentation ProfilesApplication 63172493Pending
- Methods And Systems For Cell-free Dna Fragment Size Densities To Assess CancerApplication 63163434Pending
- Methods And Systems For Cell-free Dna Fragment Size Densities To Assess CancerApplication 63067244Pending
- Cancer Diagnosis And Treatment Response Screening With Fragmentomics And Methylation AnalysisApplication PCTUS2025047392Pending
- Delfi-derived Cell-free Dna Fragmentation Patterns Differentiate Histologic Subtypes Of Lung Cancers In A Non-invasive MannerApplication 19154715Pending
- Workflows For Discovery And Deployment Of Diagnostic Assays Combining Proteomic And Genomic InformationApplication PCTUS2025026069Pending
- Cancer Diagnosis And Treatment Response Screening With Fragmentomics And Methylation AnalysisApplication 63697990Pending
- Workflows For Discovery And Deployment Of Diagnostic Assays Combining Proteomic And Genomic InformationApplication 63637831Pending
- Delfi-derived Cell-free Dna Fragmentation Patterns Differentiate Histologic Subtypes Of Lung Cancers In A Non-invasive MannerApplication PCTUS2024015444Pending
- Incorporating Clinical Risk Into Biomarker-based Assessment For Cancer Pre-screeningApplication PCTUS2023034705Pending
Related companies, and why
- ADVANCED GENOMIC TECHNOLOGY, LLCSimilar federal contract value in Medtech · null in contracts
- PLUMERIA THERAPEUTICS, INC.Similar federal contract value in Medtech · null in contracts
- CACTUS MEDICAL,LLCSimilar federal contract value in Medtech · null in contracts
- TacSense, LLCSimilar federal contract value in Medtech · null in contracts
- Claronav, Inc.Similar federal contract value in Medtech · null in contracts
- Soros, Inc.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .